Tech Company Financing Transactions
Kinvard Bio Funding Round
Kinvard Bio, operating out of Raleigh, secured $2.7 million from Carb-X.
Transaction Overview
Company Name
Announced On
7/29/2025
Transaction Type
Venture Equity
Amount
$2,700,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the advancement of its OPP program targeting high-priority pathogens responsible for serious lower respiratory tract infections (LRTIs) and skin and soft tissue infections (SSTIs).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Raleigh, NC Undisclosed
USA
Raleigh, NC Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Kinvard Bio, a spin-out from the prestigious Myers Lab at Harvard University's Department of Chemistry and Chemical Biology, is pioneering the development of a new and differentiated class of ribosome-targeting antibacterials known as oxepanoprolinamides (OPPs). With a focus on addressing the highest unmet patient need and commercial potential, Kinvard Bio's OPP class of antibacterials presents substantial therapeutic potential across multiple clinical indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lloyd Payne
Browse more venture capital transactions:
Prev: 7/29/2025: Psylink venture capital transaction
Next: 7/29/2025: Pahr Therapeutics venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs